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Abstract
The orphan receptor GPR80 (also called GPR99) was recently reported to be the P2Y15 receptor activated by AMP and
adenosine and coupled to increases in cyclic AMP accumulation and intracellular Ca
2+ mobilization (Inbe et al. J Biol
Chem 2004; 279: 19790–9 [12]). However, the cell line (HEK293) used to carry out those studies endogenously expresses
A2A and A2B adenosine receptors as well as multiple P2Y receptors, which complicates the analysis of a potential P2Y
receptor. To determine unambiguously whether GPR80 is a P2Y receptor subtype, HA-tagged GPR80 was either stably
expressed in CHO cells or transiently expressed in COS-7 and HEK293 cells, and cell surface expression was verified by
radioimmunoassay (RIA). COS-7 cells overexpressing GPR80 showed a consistent twofold increase in basal inositol
phosphate accumulation. However, neither adenosine nor AMP was capable of promoting accumulation of either cyclic
AMP or inositol phosphates in any of the three GPR80-expressing cells. A recent paper (He et al. Nature 2004; 429:
188–93 [15]) reported that GPR80 is a Gq-coupled receptor activated by the citric acid cycle intermediate, a-
ketoglutarate. Consistent with this report, a-ketoglutarate promoted inositol phosphate accumulation in CHO and
HEK293 cells expressing GPR80, and pretreatment of GPR80-expressing COS-7 cells with glutamate dehydrogenase,
which converts a-ketoglutarate to glutamate, decreased basal levels of inositol phosphates. Taken together, these data
demonstrate that GPR80 is not activated by adenosine, AMP or other nucleotides, but instead is activated by a-
ketoglutarate. Therefore, GPR80 is not a new member of the P2Y receptor family.
Abbreviations: ADA–adenosine deaminase; Ado–adenosine; GluDH–glutamate dehydrogenase; HA–hemagglutinin;
HBSS–Hank’s balanced salt solution; PBS–phosphate-buffered saline; PPADS–pyridoxal-phosphate-6-azophenyl-2S,
4S-disulphonic acid; RIA–radioimmunoassay
Introduction
Extracellular adenine and uridine nucleotides exert their
physiological effects through two main receptor families:
The ligand-gated ion channel P2X receptors and the G
protein-coupled P2Y receptors [1]. Molecular cloning and
functional studies by a number of laboratories have
identified eight functional mammalian P2Y receptor sub-
types (P2Y1, P2Y2, P2Y4, P2Y6,P 2 Y 11, P2Y12,P 2 Y 13, and
P2Y14) [2]. These receptors can be subdivided pharmaco-
logically into the adenosine nucleotide-preferring P2Y
receptors activated primarily by ATP and/or ADP (P2Y1,
P2Y11,P 2 Y 12, and P2Y13), the uridine nucleotide-prefer-
ring receptors (P2Y4, P2Y6, and P2Y14) activated by UTP,
UDP or UDP sugars, and a receptor (P2Y2) activated
equipotently by both ATP and UTP. From a phylogenetic,
structural, and signaling point of view, P2Y receptors fall
into two subfamilies. The P2Y1 receptor subfamily, which
encompasses P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11 recep-
tors, shares 35%–52% sequence identity (with exception of
28%–30% identity of the P2Y11 receptor to the other four
members) and couples to Gq thereby activating phospho-
lipase C. The P2Y12 receptor subfamily, which includes
P2Y12, P2Y13, and P2Y14 receptors, is located in a gene
cluster on chromosome 3, shares 45%–55% identity, and
couples to Gi/o and thereby inhibits adenylyl cyclase.
The identification and naming of new P2Y receptors has
been controversial and has led to considerable confusion in
P2Y receptor nomenclature. For example, four receptors
were originally identified as P2Y receptors (P2Y5, P2Y7,
P2Y9, and P2Y10) [3, 4] but were shown later either to not
respond to nucleotides (P2Y5, P2Y7) [5, 6] and/or to be
activated by a non-nucleotide ligand (P2Y7, P2Y9) [7, 8].
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Xenopus P2Y8 [10] receptors, are likely species homo-
logues of human P2Y6 and P2Y4 receptor subtypes,
respectively [11]. Problems in identifying new P2Y
receptors arise in part because of (1) the low sequence
identity between bona fide P2Y receptor subtypes, (2) the
lack of a generally applicable radioligand for P2Y
receptors, (3) endogenous expression of one or more
subtypes of P2Y and adenosine receptors on model cell
lines in which potentially new receptors are expressed and
characterized, and (4) extracellular metabolism and inter-
conversion of nucleotides, which can lead to unintended or
misleading responses to added nucleotides. Thus, identifi-
cation of a new receptor in the P2Y family requires
rigorous demonstration of receptor activity.
Recently, the orphan receptor GPR80 (also called
GPR99), which encodes a protein of 337 amino acids with
25%–36% sequence identity (43%–58% similarity) to
members of the P2Y1 receptor subfamily, was reported to
be the P2Y15 receptor and to mediate AMP- and adenosine-
promoted increases in cyclic AMP accumulation and
mobilization of intracellular Ca
2+ [12]. However, the cell
line (HEK293) used to examine the pharmacological
selectivity of recombinant GPR80 endogenously expresses
P2Y1, P2Y2, P2Y4, P2Y12 and P2Y13 receptors as well as
A2A and A2B adenosine receptors [12–14], which markedly
obfuscates the potential study of recombinant receptors
activated by either nucleotides or nucleosides. Moreover, a
recent study reported activation of GPR80 by the citric acid
cycle intermediate a-ketoglutaric acid [15], which further
calls into question the assertion that GPR80 is a receptor
for adenosine and AMP.
To determine unambiguously whether GPR80 is a new
P2Y receptor subtype, HA-tagged GPR80 was stably
expressed in CHO cells or transiently expressed in COS-7
and HEK293 cells, and activation by AMP and adenosine
was evaluated by measuring both inositol phosphate and
cyclic AMP accumulation. Our data demonstrate that
GPR80 is not activated by adenosine, AMP, or any
other nucleotides, but instead is activated by the citric
acid cycle intermediate, a-ketoglutarate, as reported by
He et al. [15].
Materials and methods
Materials
All cell culture reagents were supplied by the tissue culture
facility in the Lineberger Comprehensive Cancer Center
(University of North Carolina at Chapel Hill). AMP,
adenosine, ADP, UDP, a-ketoglutarate, adenosine deami-
nase (ADA), Ro20-1724, glutamate dehydrogenase, and
carbachol were from Sigma (St Louis, Missouri, USA).
ATP, UTP, and the transfection reagent FuGENE6 were
from Roche Biochemicals (Indianapolis, Indiana, USA).
Forskolin was purchased from Calbiochem (La Jolla,
California, USA). Suramin and PPADS (pyridoxal-phos-
phate-6-azophenyl-2S,4 S-disulphonic acid) were from RBI
(Natick, Massachusetts, USA).
Construction of HA-tagged GPR80 cDNA
The coding sequence of GPR80 was amplified by PCR
with Pfu polymerase (Stratagene) from human genomic
DNA. The 5S primer (5S-GAGACGCGTCCAATGAGC
CACTAGACTATTTA-3S) was complementary to codons
2–7 of GPR80 and contained an MluI site at the 5S end,
while the 3S primer (5S-AGACTCGAGTCAAGGGTTGTT
TGAGTAACTGATT-3S) was complementary to codons
337–331 and contained a XhoI site following the stop
codon. The amplified cDNA was digested with MluI and
XhoI and ligated in-frame into a similarly digested pLXSN
retroviral expression vector containing an upstream EcoRI
restriction site, Kozak initiation sequence, initiating methi-
onine residue, and the hemagglutinin (HA) epitope tag
(YPYDVPDY) to yield pLXSN-GPR80. To construct
pcDNA3-GPR80, pLXSN-GPR80 was digested with
EcoRI and XhoI and ligated into the similarly digested
expression vector, pcDNA3.
Transient expression of GPR80 in COS-7
and HEK293 cells
All cells were maintained in DMEM-High Glucose
(DMEM-H) with 10% serum. Transient transfection of
COS-7 and HEK293 cells was performed according to
protocols supplied with the FuGENE6 reagent. Briefly,
1.510
6 cells per 60-mm dish were incubated overnight
in 4 ml medium. The next day, 8 ml FuGENE6 and 2.8 mg
of either pcDNA3 or pcDNA3-GPR80 in 400 ml serum-free
DMEM-H was added to the cells for 5–6 h. The transfected
cells then were trypsinized and seeded in 24-well plates for
assays.
Stable expression of GPR80 in CHO cells
The procedure for stable receptor expression was described
in detail previously [16]. Briefly, recombinant retrovirus
particles were produced by calcium phosphate-mediated
transfection of PA317 cells with pLXSN or pLXSN-
GPR80 and used to infect CHO cells. Geneticin-resistant
cells were selected with DMEM-H containing 1 mg/ml
G418.
Assays for inositol phosphate and cyclic
AMP accumulation
CHO cells were seeded in 24-well plates at 510
4 cells/
well and assayed 3 days later. For transiently transfected
COS-7 and HEK293 cells, 210
5 cells/well were seeded
in 24-well plates and assayed 2 days later. Inositol lipids
were radiolabelled by overnight incubation of the cells
with 200 ml serum-free, inositol-free DMEM containing
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3H]inositol per well. Agonists or antagonists
were added at 5 concentration in 50 ml of 50 mM LiCl,
250 mM HEPES, pH 7.25. Following a 10-min incubation
(30 min incubation in Figures 1C and 5) at 37 -C, the
reaction was terminated by aspirating the medium and
adding 0.75 ml boiling EDTA, pH 8.0. [
3H]Inositol
phosphates were resolved with Dowex AG1-X8 columns.
To monitor cyclic AMP accumulation, cells were labeled
with 200 ml serum-free DMEM containing 0.8 mCi of
[
3H]adenine for 2 h. Twenty minutes prior to the assay,
cells were supplemented with 50 mM HEPES, pH 7.4.
Ro20-1724 (100 mM), which in contrast to IBMX used by
Inbe and coworkers [12] does not inhibit adenosine
receptors, was added 10 min prior to the initiation of the
assay to inhibit cyclic nucleotide phosphodiesterases.
Drugs were added at 6 concentration in 50 ml of Hank’s
balanced salt solution (HBSS) for 10 min at 37 -C.
Reactions were terminated by aspiration of the drug-
containing medium and addition of 1 ml of ice-cold 5%
trichloroacetic acid. [
3H]Cyclic AMP was purified using
Dowex and alumina columns and quantified by scintilla-
tion counting.
Radioimmunoassay (RIA) to quantify cell
surface expression
Cells were seeded in 24-well plates at the densities
described above and assayed 2–3 days later as described
previously [17]. Cells were fixed in 4% paraformaldehyde,
washed, blocked, and then incubated with a 1:1,000
dilution of mouse anti-HA monoclonal antibody (clone
HA.11) for 1 h. Cells were washed twice with HBSS
containing 1 mM Ca
2+ and Mg
2+, followed by incubation
with [
125I]-labeled rabbit anti-mouse antibody. After
incubating for 2 h, the cells were washed twice with HBSS
containing Ca
2+ and Mg
2+, solubilized with 1 M NaOH,
and transferred to glass tubes for quantitation of radioac-
tivity by g-counting.
Figure 1. Lack of adenosine- and AMP-promoted inositol phosphate accumulation in COS-7 cells transiently expressing GPR80. COS-7 cells were
transfected with pcDNA3 or pcDNA3-HA-GPR80 and analyzed for cell surface expression and receptor activity. A) Quantitation of cell surface
expression of HA-tagged GPR80 by RIA. B) Cells were transfected with the indicated plasmids and the capacity of adenosine (Ado) and AMP to
increase inositol phosphate accumulation over 10 min was measured. C) GPR80-expressing COS-7 cells were incubated for 30 min with adenosine
deaminase (ADA), suramin, or PPADS at the indicated concentrations, followed by addition of LiCl and incubation for a further 30 min. Data shown are
the mean from triplicate assays from three separate experiments.
GPR80/99 is not the P2Y15 receptor 69Results
Transient expression of GPR80 in COS-7 cells
To identify the ligand(s) that activate GPR80, we first
expressed the HA-tagged receptor transiently in COS-7
cells. GPR80 was well expressed in COS-7 cells as
determined by a cell-surface RIA (Figure 1A). To assess
the capacity of adenosine or AMP to activate GPR80,
COS-7 cells were transfected with pcDNA3 or pcDNA3-
GPR80 either with or without a plasmid encoding chimeric
Gqia [18], and then challenged with high concentrations
(up to 100 mM) of adenosine or AMP. Gqia is a chimeric
Ga subunit in which the last five amino acids of Gqa have
been replaced with the corresponding residues from Gia,
allowing Gi-coupled receptors to activate phospholipase C
and increase inositol phosphate accumulation.
Neither adenosine nor AMP promoted inositol phos-
phate accumulation in either vector- or GPR80-transfected
cells (Figure 1B). Similarly, ATP, ADP, UTP, UDP and
UDP-glucose (all at 100 mM) failed to promote inositol
phosphate accumulation (data not shown).
1 However, we
consistently observed an approximately twofold increase in
basal inositol phosphate accumulation in GPR80-trans-
fected cells compared to vector-transfected cells, and this
increase in basal levels was not affected by co-expression
of Gqia. The increase in basal inositol phosphate levels in
GPR80-transfected cells and the absence of a further
increase when GPR80 was co-expressed with Gqia
suggests that GPR80 is coupled to Gq/phospholipase C.
The GPR80-dependent increase of basal inositol phos-
phate accumulation could be due either to constitutive
activity of the receptor or to the activation of GPR80 by
endogenously released compounds. To assess whether
adenosine is released and activates the receptor, cells were
preincubated with 1 or 4 U/ml of adenosine deaminase for
1 h prior to the addition of Li and incubation for an
additional 30 min. No decrease in inositol phosphate accu-
mulation was observed in the presence of the adenosine-
metabolizing enzyme (Figure 1C). We also tested the
capacity of non-selective P2 receptor antagonists, PPADS
and suramin, to inhibit basal accumulation of inositol
phosphates, but both of these compounds had no effect.
Stable expression of GPR80 in CHO cells
CHO cells were utilized as an additional cell line to
investigate the signaling properties of GPR80. HA-tagged
GPR80 was stably expressed in CHO cells following
retroviral infection, and immunoassays indicated that the
receptor was well expressed in CHO cells (Figure 2A).
Neither AMP nor adenosine (at 100 mM) promoted inositol
Figure 2. Lack of adenosine- and AMP-promoted second messenger signaling in CHO cells stably expressing GPR80. GPR80 was stably expressed in
CHO cells by retroviral infection and selection of G418-resistant cells. A) Quantitation of cell surface expression of HA-tagged receptors by RIA. P2Y11
refers to CHO cells stably expressing the HA-P2Y11 receptor. B) Adenosine (Ado), AMP and carbachol were added to wild-type and GPR80-expressing
CHO cells, and their capacity to promote [
3H]inositol phosphate accumulation was assessed. C) ATP (100 mM) was added to wild-type and P2Y11
receptor-expressing CHO cells for 10 min, followed by measurement of [
3H]inositol phosphates accumulation. D) The capacity of adenosine (Ado),
AMP and forskolin to increase [
3H]cyclic AMP accumulation in wild-type and GPR-80 expressing CHO cells was measured. Data shown are the mean
from triplicate assays from three separate experiments.
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In contrast, carbachol, which activates an endogenous
muscarinic receptor, promoted a robust increase in inositol
phosphates in both wild-type and GPR80-expressing cells
(Figure 2B), and ATP (100 mM) promoted large increases
in inositol phosphate accumulation in CHO cells exoge-
nously expressing the P2Y11 receptor (Figure 2C). These
data provide additional data in a different cell line demon-
strating that neither AMP nor adenosine is an agonist
for GPR80.
Transient expression of GPR80 in HEK293 cells
The studies of Inbe et al. [12] reporting AMP- and
adenosine-promoted increases in intracellular calcium
mobilization and cyclic AMP accumulation were carried
out in HEK293 cells transiently transfected with GPR80.
Although we did not observe the agonist activity of AMP
or adenosine at GPR80 in either COS-7 or CHO cells, the
possibility remained that an endogenous factor exists in
HEK293 that combines with GPR80 to convey nucleotide/
nucleoside sensitivity to the receptor. To test this possibil-
ity, we transiently expressed GPR80 in HEK293 cells and
tested the capacity of ATP, AMP and adenosine to promote
inositol phosphate or cyclic AMP accumulation. Although
HA-tagged GPR80 was well expressed in HEK293 cells
(Figure 3A), neither AMP nor adenosine (up to 100 mM)
promoted increases in inositol phosphate accumulation
(Figure 3B) in cells transfected with GPR80 compared to
the cells transfected with empty vector. A slight increase in
inositol phosphate accumulation was observed with ATP,
which presumably occurred due to activation of endoge-
nous P2Y1 and P2Y2 receptors in HEK293 cells [13]. Both
AMP and adenosine promoted cyclic AMP accumulation
in HEK293 cells, but no difference was observed in cells
transfected with empty vector versus cells expressing
GPR80 (Figure 3C). Taken together, our data in three
different cell lines demonstrate that GPR80 is not a
receptor for either adenosine or AMP.
A citric acid cycle intermediate, a-ketoglutarate, is an
agonist for GPR80
During the course of this work, a-ketoglutarate, a citric acid
cycle intermediate, was reported to activate GPR80,
promoting intracellular calcium mobilization and inositol
phosphate accumulation through a Gq-mediated pathway
[15]. To confirm these results, we assessed the capacity of
a-ketoglutarate to promote inositol phosphate accumulation
in CHO-GPR80 and in GPR80-transfected HEK293 cells.
As shown in Figure 4, a-ketoglutarate increased inositol
phosphate accumulation in a concentration-dependent man-
ner in both cell lines, with an EC50 of 140T10 mM in CHO-
GPR80 cells and 160T20 mM in HEK293-GPR80 cells.
As shown above (Figures 1B and C), expression of
GPR80 in COS-7 cells resulted in increased basal accumu-
lation of inositol phosphates. To determine if GPR80-
dependent increases in inositol phosphate accumulation was
Figure 3. Lack of adenosine- and AMP-promoted second messenger signaling in GPR80-expressing HEK293 cells. HEK293 cells were transiently
transfected with empty vector or pcDNA3-HA-GPR80, and analyzed for cell surface expression and receptor activity. A) Quantitation of cell surface
expression of HA-tagged GPR80 by RIA. B) Quantitation of [
3H]inositol phosphate accumulation in empty vector- and GPR80-transfected HEK293
cells in response to the indicated agents. C) Quantitation of [
3H]cyclic AMP accumulation in empty vector- and GPR80-transfected cells in response to
the indicated agents. Data shown are the mean from triplicate assays from three separate experiments.
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utilized the enzyme glutamate dehydrogenase (GluDH),
which catalyzes the conversion of a-ketoglutarate to
glutamate in the presence of NADH, NH4
+, and ADP.
COS-7 cells expressing GPR80 or empty vector were pre-
incubated for 60 min with PBS, reaction buffer (135 mM
NADH, 200 mMN H 4Cl, 85 mM EDTA, and 100 mM ADP,
final concentrations), or reaction buffer plus GluDH, and
basal accumulation of inositol phosphate accumulation was
assessed. As seen in Figure 5, pre-incubation with GluDH
significantly lowered basal inositol phosphate accumulation
in GPR80-expressing cells, although the levels were still
higher than those in empty vector-transfected COS-7 cells.
Discussion
The nomenclature for P2Y receptors is confusing at best.
Six receptors have erroneously been designated as P2Y
receptors, which has led to considerable confusion and
controversy in the P2 receptor field. Thus, all reports of
potential new P2Y receptors should be viewed with caution
until the results are independently verified by other labs.
We show here that GPR80, which was reported to be the
P2Y15 receptor activated by adenosine and AMP [12], is
not a receptor for these compounds, and, consequentially,
should not be included in the P2Y receptor family. By
either stably or transiently expressing GPR80 in three
different cell lines (COS-7, CHO, and HEK293), we have
provided compelling evidence that although GPR80 is a
functional Gq-coupled receptor, it is not activated by
adenosine, AMP and other common nucleotides and
nucleotide sugars, but instead is activated by the citric
acid cycle intermediate, a-ketoglutarate, as first reported
by He and coworkers [15].
In the study by Inbe et al. [12], AMP and adenosine
promoted both intracellular Ca
2+ mobilization and cyclic
AMP accumulation in HEK293 cells expressing GPR80 but
not in wild-type cells. However, our data from three
different cell lines expressing GPR80, including HEK293
cells, demonstrate that AMP and adenosine have no such
activity. What might be the source(s) of this discrepancy?
Our data with HEK293 cells demonstrate that adenosine
and to a lesser extent AMP promote robust cyclic AMP
accumulation, whether or not GPR80 was expressed in
these cells. Perhaps the stimulation of cyclic AMP
accumulation in HEK293 cells stably expressing GPR80
versus wild-type HEK293 cells reflects a difference in the
level of endogenous receptors expressed in the two cell
lines, leading to the erroneous conclusion that stimulation
was due to activation of GPR80. The Ca
2+ mobilization
response to adenosine and AMP observed in GPR80 cells
also may have been due to differential expression of
endogenous P2Y receptors and their activation by small
amounts of contaminating nucleotides or by bioconversion
of added nucleotides by ecto-enzymes. This is particularly
relevant given the fact that the signal amplification inherent
in Ca
2+ measurements can result in large signals from
activation of a receptor even at low receptor occupancy.
Although we were unable to observe a response to
adenosine or AMP in GPR80-expressing COS-7 and CHO
cells, one possibility to explain the discrepancy between
our results and those of Inbe et al. [12] is that the HEK293
cells used to express GPR80 in the previous study might
express an endogenous factor that was required for receptor
activity. For example, P2Y1,P 2 Y 2,P 2 Y 4,P 2 Y 12 and
P2Y13 receptors or A2a and A2b receptors, all of which
are expressed in HEK293 cells [12–14], might potentially
form a heterodimer with overexpressed GPR80 and result
in a receptor with novel pharmacological selectivity. For
example, this phenomenon has been observed with mu and
delta opioid receptors [19, 20] and with GABAB receptors
[21] as well as with other receptors [22]. However, as in
Figure 5. Pre-incubation of COS-7 cells expressing GPR80 with
glutamate dehydrogenase decreases basal accumulation of inositol
phosphates. Transfected COS-7 cells labeled overnight with myo-[
3H]ino-
sitol were pre-incubated for 60 min with 50 ml PBS, reaction buffer (RB;
NADH 135 mM, NH4Cl 200 mM, EDTA 85 mM, and ADP 100 mM, final
concentration), or reaction buffer plus GluDH. Accumulation assays in the
absence of added agonist were initiated by adding LiCl (10 mM final) and
allowed to proceed for 30 min. Data shown are the mean from triplicate
assays from three separate experiments. * PG0.05 (reaction buffer+GluDH
versus PBS and reaction buffer+GluDH versus reaction buffer alone,
unpaired t-test).
Figure 4. GPR80 is activated by a-ketoglutarate, a citric acid cycle
intermediate. CHO and HEK293 cells expressing GPR80 were challenged
with a-ketoglutarate and [
3H]inositol phosphate accumulation was
measured. Data shown are the mean from triplicate assays from three
separate experiments.
72 A.-D. Qi et al.COS-7 and CHO cells, expression of GPR80 in HEK293
cells did not confer capacity of either adenosine or AMP to
increase inositol phosphate or cyclic AMP accumulation
over levels observed in vector-transfected cells. Thus,
heterodimerization or expression of an endogenous factor
in HEK293 cells apparently does not explain the results of
Inbe et al. [12].
Interestingly, we consistently observed a twofold in-
crease in basal inositol phosphate accumulation when
GPR80 was expressed in COS-7 cells. This increase in
basal inositol phosphate accumulation was reminiscent of
increases observed upon expression of P2Y receptors in
1321N1 astrocytoma and other cell lines [23], which is due
to the cellular release of nucleotides and autocrine/para-
crine receptor activation [24]. We reasoned that the
increased basal accumulation of inositol phosphates might
also be due to release of an endogenous compound(s) that
activated GPR80. The increased basal accumulation was
not affected by increasing adenosine deaminase levels in
the medium (Figure 1C), suggesting that adenosine was not
the activating endogenous compound. Upon confirmation
that GPR80 was activated by a-ketoglutarate, we investi-
gated whether the increased basal inositol phosphates was
due to release of a-ketoglutarate and subsequent autocrine/
paracrine activation of the receptor. Indeed, addition of
GluDH, which converts a-ketoglutarate to glutamate,
significantly decreased the basal levels of inositol phos-
phate accumulation when added 60 min prior to addition of
LiCl (to block inositol monophosphatase), although this
decrease represented only a fraction of the total increase.
Several possibilities might explain the relative impotence
of GluDH in reducing basal accumulation of inositol
phosphate accumulation in GPR80-expressing cells. These
include: (1) addition of a suboptimal amount of enzyme
(the maximum amount added was 10 U/ml), (2) inability of
the enzyme to reduce a-ketoglutarate levels in the
Funstirred layer` at the extracellular surface of the cells
[25], and (3) relatively low levels of inositol mono-
phosphatase in COS-7 cells, which would result in
substantial amount of GluDH-insensitive inositol phos-
phate accumulation prior to the addition of LiCl. Whatever
the reason, our results do suggest that a-ketoglutarate
release is involved in increased basal activity of GPR80.
Surprisingly, the increase in basal accumulation of
inositol phosphates was observed only in COS-7 cells and
not in CHO or HEK293 cells. Although this observation
suggests that only COS-7 cells release a-ketoglutarate into
the medium, an alternative explanation follows from the
fact that COS-7 cells contain the SV40 large T antigen,
which supports runaway plasmid replication following
transfection with plasmids (such as pcDNA3) containing
the SV40 origin of replication and eventually results in
lytic death [26]. Thus, cell death may occur following
transfection of COS-7 cells resulting in release of intracel-
lular compounds, including a-ketoglutarate.
One interesting aspect of this work and that of He et al.
[15] is the relatively low potency of a-ketoglutarate for
activation of GPR80. The potency of a-ketoglutarate
ranged from 32 and 69 mM in the aequorin and FLIPR
assays, respectively, described by He and coworkers [15]
to õ150 mM in inositol phosphate accumulation assays
reported here (Figure 4). These values are considerably
higher than the potency of most natural nucleotides for
activation of P2Y receptors. However, the citric acid cycle
ensures a large reservoir of a-ketoglutarate and the mean
level of a-ketoglutarate in rat plasma is about 25 mM
[27, 28]. Given that a-ketoglutarate has the potential to be
released from cells in a regulated fashion following receptor
activation or mechanical stimulation, the levels of extracel-
lular a-ketoglutarate could easily reach levels sufficient for
activation of GPR80. Moreover, the recent work by Joseph
and coworkers [25] has highlighted the lack of correlation
between the concentrations of nucleotides in the bulk
medium versus at the extracellular surface. Thus, the
relatively high EC50 may allow relevant extracellular
regulation of GPR80 under physiological conditions.
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Note
1. Small increases of similar magnitude were observed in both vector-
and GPR80-transfected cells upon addition of ATP, ADP, and UTP,
presumably from activation of endogenous P2Y1 and P2Y2 receptors.
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